dpp 4 inhibitor and glp 1 agonist GLP-1 receptor agonists or DPP-4 inhibitors: How to guide the clinician? GLP-1-RA and DPP-4 inhibitors in

32 Anti-exendin-4 antibody levels in serum In the light of reports of the development of anti-exenatide antibody in human studies administering exenatide in type 2 diabetes mellitus 33,34 (with anti-exenatide titres peaking between 6 and 22 weeks), as well as their presence in preclinical studies, 32,35 we investigated whether such antibodies developed in our clinical study

Lipopolysaccharide (LPS), a prototypical bacterial endotoxin, has been identified as a key mediator linking microbial dysbiosis to GLP-1 activation

Safety and efficacy of once-weekly semaglutide vs additional oral antidiabetic drugs in Japanese people with inadequately controlled type 2 diabetes: A randomized trial

Rosenstock J, Reusch J, Bush M, Yang F, Stewart M